|
| 情况下 |
治疗建议 |
OS / LR联合化疗估计(%) |
OS / LR PERSARC预后(%) |
∆预后(∆- %绝对) |
| 操作系统 |
LR |
操作系统 |
LR |
∆操作系统 |
∆LR |
|
| 1 |
R1 |
92.5 |
30.0 |
74.2 |
22.8 |
18.3 |
7.2 |
| 4 |
新辅助RT, R1 |
82.5 |
5.0 |
41.1 |
15.8 |
41.4 |
−10.8 |
| 6 |
新辅助RT, R1 |
27.5 |
20.0 |
14.0 |
20.4 |
13.5 |
−0.4 |
| 7 |
新辅助RT, R1 |
70.0 |
12.5 |
55.4 |
13.6 |
14.6 |
−1.1 |
| 8 |
R0 |
20.0 |
17.5 |
25.9 |
13.1 |
−5.9 |
4.4 |
| 9 |
新辅助RT, R1 |
40.0 |
15.0 |
77.0 |
10.0 |
−37.0 |
5.0 |
| 10 |
新辅助RT, R2 |
65.0 |
17.5 |
71.7 |
15.3 |
−6.7 |
2.2 |
| 13 |
新辅助RT, R1 |
82.5 |
5.0 |
72.7 |
10.9 |
9.8 |
−5.9 |
| 14 |
新辅助RT, R2 |
57.5 |
22.5 |
29.9 |
24.3 |
27.6 |
−1.8 |
| 15 |
新辅助RT, R0 |
65.0 |
17.5 |
81.3 |
2.9 |
−16.3 |
14.6 |
| 16 |
新辅助RT, R0 |
80.0 |
5.0 |
71.1 |
5.0 |
8.9 |
0.0 |
| 17 |
新辅助RT, R1 |
82.5 |
12.5 |
80.4 |
8.7 |
2.1 |
3.8 |
| 18 |
新辅助RT, R0 |
72.5 |
7.5 |
76.7 |
4.4 |
−4.2 |
3.1 |
| 19 |
R0 |
70.0 |
45.0 |
54.7 |
13.9 |
15.3 |
31.1 |
| 20. |
新辅助RT, R0 |
72.5 |
10.0 |
79.0 |
2.3 |
−6.5 |
7.7 |
| 21 |
新辅助RT, R0 |
80.0 |
5.0 |
77.0 |
4.8 |
3.0 |
0.2 |
| 22 |
新辅助RT, R0 |
75.0 |
10.0 |
57.6 |
6.6 |
17.4 |
3.4 |
| 23 |
新辅助RT, R1 |
62.5 |
12.5 |
49.2 |
10.0 |
13.3 |
2.5 |
| 24 |
R1,辅助RT |
17.5 |
55.0 |
37.1 |
29.9 |
−19.6 |
25.1 |
| 25 |
新辅助RT, R1 |
40.0 |
22.5 |
70.7 |
7.8 |
−30.7 |
14.7 |
| 26 |
新辅助RT, R1 |
60.0 |
20.0 |
79.7 |
9.3 |
−19.7 |
10.7 |
| 27 |
新辅助RT, R1 |
60.0 |
10.0 |
71.8 |
10.0 |
−11.8 |
0.0 |
| 28 |
R2 |
12.5 |
100.0 |
28.9 |
27.3 |
−16.4 |
72.7 |
| 29日 |
新辅助RT, R0 |
65.0 |
10.0 |
41.8 |
4.9 |
23.2 |
5.1 |
| 30. |
新辅助RT, R1 |
15.0 |
30.0 |
44.0 |
10.2 |
−29.0 |
19.8 |
| 31日 |
新辅助RT, R0 |
85.0 |
10.0 |
77.9 |
3.0 |
7.1 |
7.0 |
| 32 |
R2 |
5.0 |
30.0 |
17.1 |
52.8 |
−12.1 |
−22.8 |
| 33 |
新辅助RT, R1 |
20.0 |
20.0 |
53.1 |
12.9 |
−33.1 |
7.1 |
| 34 |
新辅助RT, R1 |
35.0 |
25.0 |
59.4 |
9.4 |
−24.4 |
15.6 |
| 35 |
新辅助RT, R0 |
60.0 |
10.0 |
66.6 |
5.5 |
−6.6 |
4.5 |
| 36 |
新辅助RT, R0 |
65.0 |
10.0 |
79.9 |
4.3 |
−14.9 |
5.7 |
|
|